A detailed history of Rafferty Asset Management, LLC transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 8,105 shares of HRMY stock, worth $299,641. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,105
Holding current value
$299,641
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$31.86 - $41.49 $258,225 - $336,276
8,105 New
8,105 $278,000
Q4 2023

Feb 13, 2024

BUY
$19.2 - $33.78 $141,580 - $249,093
7,374 New
7,374 $238,000
Q3 2022

Nov 14, 2022

BUY
$42.06 - $55.45 $1,093 - $1,441
26 Added 0.5%
5,223 $231,000
Q2 2022

Aug 12, 2022

BUY
$33.54 - $52.15 $174,307 - $271,023
5,197 New
5,197 $253,000
Q1 2022

May 13, 2022

SELL
$33.14 - $51.13 $218,226 - $336,691
-6,585 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$34.09 - $43.91 $224,482 - $289,147
6,585 New
6,585 $281,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.19B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.